Literature DB >> 33256918

SARS-CoV-2 risk misclassification explains poor COVID-19 management.

Juan Martínez Hernández1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33256918      PMCID: PMC7581374          DOI: 10.1016/S0140-6736(20)32169-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
One of the most striking facts about the COVID-19 pandemic is the notable difference in approach, attitude, control measures, case incidence, and mortality rates between eastern and western hemispheres. Results of a recent analysis show lessons to be learnt from the experiences of these countries and regions. The differences in approach and mortality could be explained, at least partially, if not totally, by the misclassification of the infectious agent risk. WHO classifies microorganisms into four risk levels according to its biosafety manual. National legislation, in accordance with this classification, regulates prevention measures and biosecurity, mainly to protect occupational health. Group 4 includes new or known agents for which there is no vaccine or treatment and which can be spread at community level. Ebola virus and variola virus are categorised as group 4 agents. Group 3, however, includes dangerous microorganisms such as Mycobacterium tuberculosis that have available antibiotic therapy and other well known control measures. When severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared in Wuhan, China, other Asian countries, Australia, and New Zealand put in place contingency plans against an infectious agent of the highest risk, not only in occupational health but also to protect the general population. Given the uncertainty about the nature and real risk of the threat, governments of these countries decided to take the strictest measures—the same measures that would have been used in a case of smallpox or plague. For this reason, protective equipment similar to that used against Ebola was used, the streets were disinfected with chlorine, patients with COVID-19 were separated from the rest of the patients in monographic centres, and mandatory individual quarantines were ordered. Then collective quarantines in the form of lockdown were implemented. By contrast, the western approach, according to a supposed risk classification of group 2 or 3, initially considered COVID-19 a new kind of influenza and determined that the general management of cases and contacts would be made in general hospitals and outpatients wards, without any type of mandatory quarantine or isolation in monographic hospitals. The European Commission debated in June, 2020, the classification of SARS-CoV-2, categorising it as a group 3 agent. This decision was strongly protested by members of the European Parliament, who disagreed and called for a group 4 categorisation.4, 5 If Europe and other countries in the western hemisphere want to achieve an epidemiological trend similar to Asian countries, then SARS-CoV-2 should be considered an agent of maximum risk in all technical approaches, clinical settings, and social levels.
  1 in total

Review 1.  Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe.

Authors:  Emeline Han; Melisa Mei Jin Tan; Eva Turk; Devi Sridhar; Gabriel M Leung; Kenji Shibuya; Nima Asgari; Juhwan Oh; Alberto L García-Basteiro; Johanna Hanefeld; Alex R Cook; Li Yang Hsu; Yik Ying Teo; David Heymann; Helen Clark; Martin McKee; Helena Legido-Quigley
Journal:  Lancet       Date:  2020-09-24       Impact factor: 79.321

  1 in total
  2 in total

Review 1.  Clinical and experimental bacteriophage studies: Recommendations for possible approaches for standing against SARS-CoV-2.

Authors:  Khashayar Shahin; Lili Zhang; Mohammad Hossein Mehraban; Jean-Marc Collard; Abolghasem Hedayatkhah; Mojtaba Mansoorianfar; Abbas Soleimani-Delfan; Ran Wang
Journal:  Microb Pathog       Date:  2022-02-10       Impact factor: 3.738

Review 2.  COVID-19 in Germany and China: mitigation versus elimination strategy.

Authors:  Guangyu Lu; Oliver Razum; Albrecht Jahn; Yuying Zhang; Brett Sutton; Devi Sridhar; Koya Ariyoshi; Lorenz von Seidlein; Olaf Müller
Journal:  Glob Health Action       Date:  2021-01-01       Impact factor: 2.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.